Search Results
May 13, 2026, 12:01 ET GrowthLoop Unveils 2026 AI and Marketing Performance Index, Highlighting that Data Issues Significantly Slow Marketing Cycles, Experimentation, and Personalization
SSOT matters: Organizations using data clouds or lakes are less likely to struggle with challenges like measuring impact (42% vs 54%) and managing manual work (31% vs 38%) compared to those relying on marketing suites for their source of truth.Insights from Leading
More news about: GrowthLoop
May 13, 2026, 11:00 ET Cath Lab Services Market Size to Reach $56.2 Billion by 2031, Globally, at 7.1% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/A11508 Cath Lab Services Ecosystem Market Segmentation By Service Type: Therapeutic vs. Diagnostic The largest cath lab services market share of over three-fourths of global revenue in 2022 was held by the therapeutic segment.
More news about: Allied Market Research
May 13, 2026, 10:48 ET Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing
the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release.Pharmaceutical-Grade vs. Research-Grade PeptidesPharmaceutical-grade (also called medical-grade) peptides are manufactured under the U.S. Food and Drug Administration's
More news about: Vector Sciences & Therapeutics
May 13, 2026, 10:00 ET Keychain Report Finds AI Adoption and Operational Investment Are Driving the Next Phase of Growth in CPG Manufacturing
manufacturers are also leaning into:Partnerships and referrals (72% PL vs 45% Non-PL)Expanded capabilities (68% PL vs 39% Non-PL)Increased investment in sales and marketing (65.9% PL vs 48% Non-PL)
More news about: Keychain
May 13, 2026, 09:00 ET Levi & Korsinsky Reminds Graphic Packaging Holding Company Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 6, 2026 - GPK
than represented.The Numbers: Promised vs. ActualAdjusted EBITDA (top of range): Promised $1.78B vs. Delivered $1.395B — a gap of $385 millionAdjusted EPS (top of range): Promised $2.78 vs. Delivered $1.80 — a gap of $0.98 per shareNet
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
Promise vs. Reality: The Gossamer Bio PROSERA Performance GapNEW YORK, May 13, 2026 /PRNewswire/ -- "We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality:
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET CIGL Investor Alert: Concorde International Group Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Fabricated Growth Narrative: Levi & Korsinsky
Promise vs. Reality: The Concorde International Group Performance GapNEW YORK, May 13, 2026 /PRNewswire/ -- "Leading integrated security provider" with "strong year over year growth going forward." That was the
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET LKQ Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in LKQ Corporation Securities Lawsuit - Contact Levi & Korsinsky
Promise vs. Reality: The LKQ Corporation Performance GapNEW YORK, May 13, 2026 /PRNewswire/ -- "Minimal integration risk." That was the promise. A $200 million revenue miss and accelerating market share losses
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Growth Projections: Levi & Korsinsky
Promise vs. Reality: The Medpace Performance GapNEW YORK, May 13, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP highlights the contrast between Medpace Holdings Inc.'s (NASDAQ: MEDP) promises and results.
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET VITL Investor Alert: Vital Farms, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Inflated Revenue Projections: Levi & Korsinsky
Promise vs. Reality: The Vital Farms Performance GapNEW YORK, May 13, 2026 /PRNewswire/ -- "At least $775 million." That was Vital Farms' final revenue promise to shareholders for fiscal year 2025. The actual
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET SINBON Electronics Partners with Nexcellent Energy to Expand Hydrogen Energy Applications Across Urban Industries
https://mma.prnewswire.com/media/2978895/Diesel_vs__Hydrogen_Fuel_Cell_Generation_Comparison.jpgLogo -
More news about: SINBON Electronics
May 13, 2026, 09:00 ET UHG Investor Alert: United Homes Group Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Nieri Allegedly Concealed Forced Sale Plan: Levi & Korsinsky
the controlling stockholder ultimately forced a sale at $1.18 per share, more than 50% below the prior trading priceInside Knowledge vs. Public StatementsPlaintiffs contend that while management publicly stated the strategic review remained "ongoing" and that the Company was
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET POET DEADLINE: Levi & Korsinsky Reminds POET Technologies Inc. Investors of Upcoming Securities Class Action Deadline
discussion of purchase order details or shipping timelines could trigger contractual termination rightsRegulatory Reality: Boilerplate vs. Specific Known RisksThe SEC requires companies to disclose specific, known risks rather than relying on generic cautionary language. As pleaded
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline
internal data raised questions about whether the efti combination was performing adequately against the control armInside Knowledge vs. Public StatementsThe securities action alleges that Defendants possessed the power and authority to control Immutep's SEC filings,
More news about: Levi & Korsinsky, LLP
May 13, 2026, 09:00 ET Harness Report Reveals AI Has Outpaced How Engineering Organizations Measure Developer Productivity
Managers are nearly four times more likely than practitioners to report no concerns about how AI productivity data might be used to evaluate them (15% vs. 4%).Fear of surveillance is widespread. 54% fear individual performance evaluations based on AI data. In addition, 46% of respondents
More news about: Harness
May 13, 2026, 08:45 ET Cohen & Steers Income Opportunities REIT, Inc. Acquires Shopping Center in Charlotte, North Carolina
economic base across the finance, technology and healthcare sectors, Charlotte's population is projected to grow faster than the U.S. average (2% annually vs. 0.7%)1. The property is 97% leased, shadow-anchored by Target and includes sector leading retail concepts such as T.J. Maxx, HomeGoods, Dick's
More news about: Cohen & Steers, Inc.
May 13, 2026, 08:00 ET CeraVe Appoints NBA Icon Carmelo Anthony as Its "Head Coach"
momentum with a series of viral Carmelo moments:HOODIE MELO RETURNSRap icon Fat Joe was seen courtside at the New York Knicks vs Philadelphia 76ers Game 2 wearing a "Hoodie Melo" graphic hoodie; even 'throwing up' Carmelo's iconic "Three to the Dome" celebration from his seatCarmelo
More news about: CeraVe
May 13, 2026, 07:45 ET Samsonite Group S.A. Announces Results for the First Quarter Ended March 31, 2026
2026 vs. 2025
More news about: Samsonite
May 13, 2026, 06:30 ET Valens Semiconductor Reports First Quarter 2026 Results
top end of our guidance," said Yoram Salinger, CEO of Valens Semiconductor. "In Audio-Video, we're continuing to see increased adoption of our VS6320 and VS3000 chipsets, as additional products based on these chips hit the market. In Automotive, Valens is focused on pushing the MIPI A-PHY ecosystem forward.
More news about: Valens Semiconductor
May 13, 2026, 06:00 ET U.S. Rents Fall for 33rd Straight Month as Surge in New Multi-family Construction Points to Continued Renter Relief
%Change vs. 2025Q1% Change vs. pre-pandemic
More news about: Realtor.com
May 13, 2026, 06:00 ET Silent Push Appoints Thomas Bain as Chief Marketing Officer
concept of preemptive cyber has not truly coalesced into reality until now with Silent Push, where teams gain a multi-faceted, intelligence-led advantage vs attackers to detect attack patterns early, often and with actionable accuracy that disrupts their opportunity to disrupt. I am more than excited to work
More news about: Silent Push
May 13, 2026, 00:45 ET THE ADECCO GROUP Q1 2026 RESULTS
HIGHLIGHTSAccelerating organic revenue growth of +5.3% TDA yoyContinued strong market share gains: Group +365 bps, Adecco +210 bps vs. key competitorsBy GBU, Adecco, +7% yoy, with growth in all regions, led by Americas +15%, APAC +8% and EMEA excl. France +7%. Akkodis -1% yoy;
More news about: The Adecco Group
May 13, 2026, 00:45 ET THE ADECCO GROUP Q1 2026 RESULTS
Accelerating organic revenue growth of +5.3% TDA yoyContinued strong market share gains: Group +365 bps, Adecco +210 bps vs. key competitorsBy GBU, Adecco, +7% yoy, with growth in all regions, led by Americas +15%, APAC +8% and EMEA excl. France +7%. Akkodis -1% yoy;
More news about: The Adecco Group
May 12, 2026, 22:44 ET Atlas AI Labs lanceert eerste toestemmingloze, door activa ondersteund token uit Dubai
13 mei 2026 /PRNewswire/ -- Atlas AI Labs FZE (Atlas), de in Dubai opgerichte dochteronderneming van Atlas Capital Team Inc., een in de VS gevestigde financiële technologie-onderneming, zal het eerste, op activa gebaseerde virtuele activa uitgeven dat beschikbaar is in een volledig toestemmingloze
More news about: Atlas Capital Team Inc.
May 12, 2026, 18:01 ET Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
with prior Phase 3 studies. In ATTAIN-MAINTAIN, the most common adverse events with Foundayo vs. placebo were nausea (18.8% vs. 4.1%), constipation (13.1% vs. 4.1%), vomiting (8.3% vs. 3.4%) or diarrhea (7.4% vs. 7.5%). Discontinuation rates due to adverse events for patients randomized to placebo or Foundayo
More news about: Eli Lilly and Company